Mucositis News and Research RSS Feed - Mucositis News and Research

Autologous haematopoietic stem cell transplantation promise for myasthenia gravis

Autologous haematopoietic stem cell transplantation promise for myasthenia gravis

Study findings in seven patients with severe myasthenia gravis support the use of autologous haematopoietic stem cell transplantation for achieving long-term remission. [More]
Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others. [More]
SciClone plans to pursue development of SGX942 in the Greater China market

SciClone plans to pursue development of SGX942 in the Greater China market

SciClone Pharmaceuticals, Inc. today announced plans to pursue development and registration of SGX942 in the Greater China market, for the treatment of oral mucositis. [More]
Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive results in its Phase 2 clinical trial, in which SGX942, a first-in-class Innate Defense Regulator (IDR), at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer. [More]
Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942. [More]
Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP). [More]
NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance the development of Soligenix's heat stabilized ricin toxin vaccine, RiVax. [More]
European Commission grants orphan drug designation to SGX301 for treatment of CTCL

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system. [More]
Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has entered into a $10 million equity purchase agreement with accredited institutional investors, Kodiak Capital Group, LLC, Kingsbrook Opportunities Master Fund LP and River North Equity, LLC. [More]
Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone. [More]
Helsinn launches Helsinn Integrative Care division at ASCO Annual Meeting

Helsinn launches Helsinn Integrative Care division at ASCO Annual Meeting

Helsinn, the Swiss Group focused on building quality cancer care, announces today that its recently launched Helsinn Integrative Care division is meeting the cancer community at booth 6033 at the American Society of Clinical Oncology Annual Meeting, May 29-June 2, Chicago, Illinois. [More]
Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen. [More]
Alternating sunitinib, everolimus not supported in advanced RCC

Alternating sunitinib, everolimus not supported in advanced RCC

Australian researchers report that an alternating regimen of sunitinib and everolimus, although feasible and low-risk in patients with advanced renal cell carcinoma, failed to meet the prespecified criteria for use or continued development. [More]
Scientists find new links between inflammation and tissue regeneration

Scientists find new links between inflammation and tissue regeneration

Almost all injuries, even minor skin scratches, trigger an inflammatory response, which provides protection against invading microbes but also turns on regenerative signals needed for healing and injury repair - a process that is generally understood but remains mysterious in its particulars. [More]
BMG Pharma S.R.L Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To FERRER INTERNACIONAL S.A.

BMG Pharma S.R.L Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To FERRER INTERNACIONAL S.A.

BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with FERRER INTERNACIONAL S.A., granting them the rights to promote, sell and market its own product GelX for the Middle East, Eastern Europe, Russia and North Africa. [More]
Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration. [More]
Soligenix closes previously announced registered public offering

Soligenix closes previously announced registered public offering

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that on December 24, 2014 it closed its previously announced registered public offering. [More]

PlasmaTech Biopharmaceuticals inks agreement to commercialize MuGard in Australia, New Zealand

PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing patient care in critical areas, has entered into an exclusive license agreement with Norgine B.V., a European specialist pharmaceutical company, for the commercialization of MuGard in Australia and New Zealand. [More]
Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID). [More]
S-1 plus radiotherapy shows promise in elderly NSCLC patients

S-1 plus radiotherapy shows promise in elderly NSCLC patients

Concurrent administration of S-1 chemotherapy and radiotherapy has a favourable impact on survival in elderly patients with locally advanced non-small-cell lung cancer, a phase II trial has found. [More]
Advertisement
Advertisement